Compare Diageo plc (DEO) vs Hims and Hers Health Inc (HIMS) Price & Performance

Diageo (DEO) trades at $84.73, down 0.06% on the day, with a bearish technical signal from moving averages. The company maintains strong profitability with a 59.47% gross margin and has beaten EPS estimates in the last three quarters. Recent news highlights marketing initiatives and a CFO transition planned for 2027. The balance sheet shows $2.65B in cash against $23.75B in total debt, with a debt-to-asset ratio improving to 48.05% in 2026.

The outlook is mixed: analyst consensus leans bullish (49% buy ratings) with a focus on the US turnaround plan, but 2026 projections show declining revenue and net income. Key risks include execution of the restructuring, competitive pressures, and regulatory challenges in markets like India. The stock offers income via dividends but faces near-term fundamental headwinds.

Hims & Hers Health trades at $29.54, up slightly by 0.24% on the day. The stock shows a bullish technical signal with moving averages supporting an uptrend, while oscillators remain neutral. Fundamentally, the company reported revenue of $2.35 billion in 2025 but swung to a net loss of $142 million in 2026, with a negative net margin of 5.51%. Analyst consensus is a 'Hold' with a price target of $32.17, but the stock faces significant headwinds from multiple securities class action lawsuits announced in early October 2026.

The outlook for HIMS is clouded by legal risks and profitability challenges despite revenue growth. Investment opportunity hinges on the company's ability to return to profitability and resolve regulatory scrutiny. Key risks include ongoing litigation, FTC complaints, and execution missteps in a competitive telehealth market. Wall Street remains cautious with 65% of analysts recommending Hold.